Market Newsdesk

September 18, 2023 6:03 am

Brunswick Corporation reports success and records at the 2023 Cannes Boat Show

CANNES, France, Sept. 18, 2023 (GLOBE NEWSWIRE) — Brunswick Corporation, (NYSE: BC), reported another record-setting display at the 2023 Cannes Yachting Festival, one of the premier trade shows in Europe, with outboard engine market share gains, major new product launches, and a global product award.

Mercury Marine set another record for engine share at the event, with 66% of the outboard engines on display, further solidifying its market share leadership position in Europe. This also marks the third consecutive year that Mercury has set record share in Cannes as demand continues to be strong for high horsepower Mercury propulsion from European boat builders and consumers.

In addition, Brunswick Boat Group launched Navan, its new premium adventure boat brand which is part of the Quicksilver family, and the first two models in the Navan line-up, the C30 and S30. Both models were extremely well received by the public with orders exceeding expectations during the show and strong dealer enthusiasm to carry the product.

Sea Ray, Boston Whaler, Navico Group, and the Company’s newest acquisition, Flite, all had displays at the event and many Brunswick products made their European debuts, including the Mercury Racing 500R, Boston Whaler 405 Conquest, Heyday H22, Sea Ray Sundancer 370, SLX400, SLX 260, and many more. Quicksilver and Veer boats with Avator electric outboard engines were also displayed during the show and on the water during a two-day Brunswick media event which involved more than 30 journalists from around the world.

“Cannes continues to be a very important show for our brands and Brunswick again had an outstanding event with more Mercury engines on display than ever before as well as an enthusiastic response from our channel partners to our Navan launch,” said Dave Foulkes, Brunswick Corporation CEO. “Our premium boat models including the Boston Whaler 405 Conquest and the Sea Ray 370 Sundancer received high interest during the show and the response to all our products from consumers, media, and dealers during the event was very strong and a testament to our continued growth in Europe.”

It was also an award-winning show for Brunswick as the Sea Ray SPX 210 won the Moteur Boat Magazine Award for best boat below 7 meters while four other Brunswick boat models were named finalists for the prestigious Best of Boats award that will be announced later this year. The Bayliner M19 and Quicksilver 805 Open are finalists in the “Best for Beginners” category, and the Navan C30 and Sea Ray SLX 260 are finalists in the “Best for Fun” category.

Additionally, Brunswick’s Freedom Boat Club, Sea Ray, Boston Whaler, Navico Group and Mercury Marine teams hosted the annual Women on the Water (WOW) event celebrating the outstanding achievements of women in Brunswick and the broader industry, and the importance and encouragement of greater diversity within the marine industry.

ABOUT BRUNSWICK

Brunswick Corporation (NYSE: BC) is the global leader in marine recreation, delivering innovation that transforms experiences on the water and beyond. Our unique, technology-driven solutions are informed and inspired by deep consumer insights and powered by our belief that “Next Never Rests™”. Brunswick is dedicated to industry leadership, to being the best and most trusted partner to our many customers, and to building synergies and ecosystems that enable us to challenge convention and define the future. Brunswick is home to more than 60 industry-leading brands. In the category of Marine Propulsion, these brands include, Mercury Marine, Mercury Racing and MerCruiser and FliteBoards. Brunswick’s comprehensive collection of parts, accessories, distribution, and technology brands includes Mercury Parts & Accessories, Land ‘N’ Sea, Lowrance, Simrad, B&G, Mastervolt, RELiON, Attwood and Whale. Our boat brands are some of the best known in the world, including Boston Whaler, Lund, Sea Ray, Bayliner, Harris Pontoons, Princecraft and Quicksilver. Our service, digital and shared-access businesses include Freedom Boat Club, Boateka and a range of financing, insurance, and extended warranty businesses. While focused primarily on the marine industry, Brunswick also successfully leverages its portfolio of advanced technologies to deliver an exceptional suite of solutions in mobile and industrial applications. Headquartered in Mettawa, IL, Brunswick has more than 18,500 employees operating in 29 countries. In 2022, Brunswick was named by Forbes as a World’s Best Employer and as one of America’s Most Responsible Companies by Newsweek, both for the third consecutive year. For more information, visit Brunswick.com.

Lee
Gordon —
Vice President – Corporate Communications, Public Relations & Public Affairs
M: (904) 860-8848 | O: (847) 735-4003

September 18, 2023 6:03 am

Ennis, Inc. Reports Results for the Quarter Ended August 31, 2023 and Declares Quarterly Dividend

Ennis, Inc. Reports Results for the Quarter Ended August 31, 2023 and Declares Quarterly Dividend

MIDLOTHIAN, Texas–(BUSINESS WIRE)–
Ennis, Inc. (the “Company”), (NYSE: EBF), today reported financial results for the second quarter ended August 31, 2023. Highlights include:

Revenues were $106.8 million for the quarter compared to $111.2 million for the same quarter last year, a decrease of $4.4 million or 4.0%.
Earnings per diluted share for the current quarter were $0.42 compared to $0.47 for the comparative quarter last year.
Our gross profit margin for the quarter was 31.0% compared to 31.7% for the comparative quarter last year.

Financial Overview

The Company’s revenues for the second quarter ended August 31, 2023 were $106.8 million compared to $111.2 million for the same quarter last year, a decrease of $4.4 million, or 4.0%. Gross profit margin was $33.1 million, or 31.0%, as compared to $35.2 million, or 31.7%, for the same quarter last year. Net earnings for the quarter were $10.9 million, or $0.42 per diluted share, as compared to $12.2 million, or $0.47 per diluted share for the same quarter last year.

The Company’s revenues for the six-month period ended August 31, 2023 were $218.1 million compared to $218.9 million for the same period last year, a decrease of $0.8 million or 0.4%. Gross profit margin was $67.1 million, or 30.8%, as compared to $69.2 million, or 31.6% for the six-month periods ended August 31, 2023 and August 31, 2022, respectively. Net earnings for the six-month period ended August 31, 2023 were $22.5 million, or $0.87 per diluted share compared to $23.8 million, or $0.92 per diluted share for the same period last year.

Keith Walters, Chairman, Chief Executive Officer and President, commented by stating, “Our results for the quarter were within our expectations. Our gross profit margin for the quarter of 31.0% is within our target range and showed improvement of 40 basis points from 30.6% in the sequential quarter ending May 31, 2023 and declined 70 basis points to 31.0% compared to 31.7% in the same prior year quarter. Our EBITDA remained relatively stable at $19.8 million or 18.5% of sales compared to the sequential quarter, $20.5 million or 18.4% of sales and compared to the same quarter last year $21.3 million or 19.1% of sales.

“Our recent acquisitions added approximately $6.5 million in revenues and $0.02 in diluted earnings per share for the quarter and $10.6 million in revenues and $0.06 in diluted earnings per share for the six-month period. These increases were offset by sales volume decline as some of our print partners have experienced slowness in their sales and reduced their outsourced work to us. We will continue to explore acquisitions that make sense and hunt for new sales in new markets and new channels. As part of our regular course of business we continue to monitor incoming order volumes so that we can proactively adjust our costs accordingly and maintain our profitability.

“We believe we have one of the strongest balance sheets in the industry, with no debt and significant cash. Our profitability and strong financial condition will allow us to continue operations and fund acquisitions without incurring debt. Given those strengths, we also anticipate timely access to credit should larger acquisition opportunities materialize. We continue to focus on delivering profitability and returns to our shareholders.”

Last quarter, the Company reported that a jury had awarded it $5 million in actual and punitive damages in a lawsuit against Wright Printing Company, its owner, CEO and other employees. The award has not been recognized in the Company’s financial reports due to post-verdict motions, including the Company’s motion for its attorney’s fees, that are still pending before the Court. The Court’s rulings on the pending motions should clarify the total amount owed to the Company for the jury verdict, attorney’s fees and interest. Given the financial disclosures made by the defendants, it appears that they have the financial wherewithal to satisfy most, if not all, of the eventual judgment. Accordingly, we anticipate recognizing the judgment as a collectible receivable after the Court rules on the pending motions. The ultimate collection of the judgment may be deferred until the defendants exhaust their appellate rights.

Non-GAAP Reconciliations

To provide important supplemental information to both management and investors regarding financial and business trends used in assessing its results of operations, from time to time the Company reports the non-GAAP financial measure of EBITDA (EBITDA is calculated as net earnings before interest expense, tax expense, depreciation, and amortization). The Company may also report adjusted gross profit margin, adjusted earnings and adjusted diluted earnings per share, each of which is a non-GAAP financial measure.

Management believes that these non-GAAP financial measures provide useful information to investors as a supplement to reported GAAP financial information. Management reviews these non-GAAP financial measures on a regular basis and uses them to evaluate and manage the performance of the Company’s operations. Other companies may calculate non-GAAP financial measures differently than the Company, which limits the usefulness of the Company’s non-GAAP measures for comparison with these other companies. While management believes the Company’s non-GAAP financial measures are useful in evaluating the Company, when this information is reported it should be considered as supplemental in nature and not as a substitute or an alternative for, or superior to, the related financial information prepared in accordance with GAAP. These measures should be evaluated only in conjunction with the Company’s comparable GAAP financial measures.

The following table reconciles EBITDA, a non-GAAP financial measure, for the three and six months ended August 31, 2023 to the most comparable GAAP measure, net earnings (dollars in thousands).

	Three months ended						Six months ended
	August 31,			August 31,			August 31,			August 31,
		2023			2022			2023			2022
Net earnings	$	10,910		$	12,194		$	22,545		$	23,821
Income tax expense		4,373			4,741			8,898			9,264
Interest expense		—			—			—			—
Depreciation and amortization		4,497			4,329			8,841			8,707
EBITDA (non-GAAP)	$	19,780		$	21,264		$	40,284		$	41,792
% of sales		18.5	%		19.1	%		18.5	%		19.1	%

In Other News

On September 15, 2023 the Board of Directors declared a quarterly cash dividend of 25.0 cents per share on the Company’s common stock. The dividend is payable on November 3, 2023 to shareholders of record on October 6, 2023.

About Ennis

Founded in 1909, the Company is one of the largest private-label printed business product suppliers in the United States. Headquartered in Midlothian, Texas, Ennis has production and distribution facilities strategically located throughout the USA to serve the Company’s national network of distributors. Ennis manufactures and sells business forms, other printed business products, printed and electronic media, integrated forms and labels, presentation products, flex-o-graphic printing, advertising specialties and Post-it® Notes, internal bank forms, plastic cards, secure and negotiable documents, specialty packaging, direct mail, envelopes, tags and labels and other custom products. For more information, visit www.ennis.com.

Safe Harbor under the Private Securities Litigation Reform Act of 1995

Certain statements that may be contained in this press release that are not historical facts are forward-looking statements that involve a number of known and unknown risks, uncertainties and other factors that could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievement expressed or implied by such forward-looking statements. The words “anticipate,” “preliminary,” “expect,” “believe,” “intend” and similar expressions identify forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for such forward-looking statements. In order to comply with the terms of the safe harbor, the Company notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These statements are subject to numerous uncertainties, which include, but are not limited to, the erosion of demand for our printer business documents as the result of digital technologies, risk or uncertainties related to the completion and integration of acquisitions, and the limited number of available suppliers and variability in the prices of paper and other raw materials. Other important information regarding factors that may affect the Company’s future performance is included in the public reports that the Company files with the Securities and Exchange Commission, including but not limited to, its Annual Report on Form 10-K for the fiscal year ending February 28, 2023. The Company does not undertake, and hereby disclaims, any duty or obligation to update or otherwise revise any forward-looking statements to reflect events or circumstances occurring after the date of this release, or to reflect the occurrence of unanticipated events, although its situation and circumstances may change in the future. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The inclusion of any statement in this release does not constitute an admission by the Company or any other person that the events or circumstances described in such statement are material.

Ennis, Inc.
Unaudited Condensed Consolidated Financial Information
(In thousands, except share and per share amounts)

	Three months ended					Six months ended
Condensed Consolidated Operating Results	August 31,					August 31,
		2023			2022		2023			2022
Revenues	$	106,760		$	111,233	$	218,054		$	218,900
Cost of goods sold		73,661			76,014		150,914			149,677
Gross profit margin		33,099			35,219		67,140			69,223
Operating expenses		18,341			17,937		36,684			35,624
(Gain) Loss from disposal of assets		52			5		52			—
Operating income		14,706			17,277		30,404			33,599
Other expense		(577	)		342		(1,039	)		514
Earnings before income taxes		15,283			16,935		31,443			33,085
Income tax expense		4,373			4,741		8,898			9,264
Net earnings	$	10,910		$	12,194	$	22,545		$	23,821

Weighted average common shares outstanding
Basic		25,886,058			25,797,097		25,858,154			25,805,419
Diluted		26,215,908			25,858,811		26,010,739			25,867,504

Earnings per share
Basic	$	0.42		$	0.47	$	0.87		$	0.92
Diluted	$	0.42		$	0.47	$	0.87		$	0.92

						August 31,			February 28,
Condensed Consolidated Balance Sheet Information							2023			2023
Assets
Current Assets
Cash						$	100,340		$	93,968
Accounts receivable, net							48,215			53,507
Inventories, net							45,653			46,834
Other							4,731			2,317
Total Current Assets							198,939			196,626
Property, plant & equipment, net							51,988			47,789
Operating lease right-of-use assets							12,164			13,133
Goodwill and intangible assets							135,486			135,907
Other							293			380
Total Assets						$	398,870		$	393,835
Liabilities and Shareholders’ Equity
Current liabilities
Accounts payable						$	13,092		$	18,333
Accrued expenses							17,655			18,067
Current portion of operating lease liabilities							4,866			4,847
Total Current Liabilities							35,613			41,247
Other non-current liabilities							20,111			21,156
Total liabilities							55,724			62,403
Shareholders’ Equity							343,146			331,432
Total Liabilities and Shareholders’ Equity						$	398,870		$	393,835

						Six months ended
						August 31,
Condensed Consolidated Cash Flow Information							2023			2022
Cash provided by operating activities						$	34,934		$	21,755
Cash used in investing activities							(15,640	)		(1,801	)
Cash used in financing activities							(12,922	)		(14,040	)
Change in cash							6,372			5,914
Cash at beginning of period							93,968			85,606
Cash at end of period						$	100,340		$	91,520

View source version on businesswire.com: https://www.businesswire.com/news/home/20230918454738/en/

Mr. Keith S. Walters, Chairman, Chief Executive Officer and President

Ms. Vera Burnett, Chief Financial Officer

Mr. Dan Gus, General Counsel and Secretary

Ennis, Inc.

Phone: (972) 775-9801

Fax: (972) 775-9820

www.ennis.com

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Packaging Retail Forest Products Manufacturing Natural Resources Other Manufacturing Office Products

MEDIA:

Logo

September 18, 2023 6:03 am

Franklin BSP Realty Trust, Inc. Announces Third Quarter 2023 Common Stock Dividend of $0.355 Per Share and Series E Cumulative Redeemable Preferred Stock Dividend of $0.46875 Per Share

Franklin BSP Realty Trust, Inc. Announces Third Quarter 2023 Common Stock Dividend of $0.355 Per Share and Series E Cumulative Redeemable Preferred Stock Dividend of $0.46875 Per Share

NEW YORK–(BUSINESS WIRE)–
Franklin BSP Realty Trust, Inc. (NYSE: FBRT) (“FBRT” or the “Company”) today announced its Board of Directors has declared a third quarter 2023 dividend of $0.355 per common share. The dividend is payable on or about October 10, 2023 to common stockholders of record as of September 29, 2023. The Board of Directors also declared a third quarter 2023 dividend on its convertible Series H Preferred Stock in an amount equal to the as-converted common dividend amount.

FBRT’s Board of Directors also declared a third quarter 2023 dividend of $0.46875 per share on its 7.50% Series E Cumulative Redeemable Preferred Stock (NYSE: FBRTPRE). This dividend is payable on October 16, 2023 to Series E preferred stockholders of record as of September 30, 2023. Since September 30, 2023 is not a business day, the effective record date is September 29, 2023, the immediately preceding business day.

About Franklin BSP Realty Trust, Inc.

Franklin BSP Realty Trust, Inc. (NYSE: FBRT) is a real estate investment trust that originates, acquires and manages a diversified portfolio of commercial real estate debt secured by properties located in the United States. As of June 30, 2023, FBRT had approximately $6.0 billion of assets. FBRT is externally managed by Benefit Street Partners L.L.C., a wholly owned subsidiary of Franklin Resources, Inc. For further information, please visit www.fbrtreit.com.

Forward-Looking Statements

Certain statements included in this press release are forward-looking statements. Those statements include statements regarding the intent, belief or current expectations of the Company and members of our management team, as well as the assumptions on which such statements are based, and generally are identified by the use of words such as “may,” “will,” “seeks,” “anticipates,” “believes,” “estimates,” “expects,” “plans,” “intends,” “should” or similar expressions. Actual results may differ materially from those contemplated by such forward-looking statements. Further, forward-looking statements speak only as of the date they are made, and we undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time, unless required by law.

The Company’s forward-looking statements are subject to various risks and uncertainties, including but not limited to the risks and important factors contained and identified in the Company’s filings with the Securities and Exchange Commission (“SEC”), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and its subsequent filings with the SEC, any of which could cause actual results to differ materially from the forward-looking statements. The forward-looking statements included in this communication are made only as of the date hereof.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230918304171/en/

Investor Relations Contact:

Lindsey Crabbe

[email protected]

(214) 874-2339

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Professional Services Commercial Building & Real Estate Finance Construction & Property REIT Banking

MEDIA:

September 18, 2023 6:03 am

Forrester Announces Full Conference Agenda For Technology & Innovation EMEA 2023

Forrester Announces Full Conference Agenda For Technology & Innovation EMEA 2023

The in-person and digital event will equip technology leaders in the region with the latest research and insights to fuel business growth using emerging technologies like generative AI

LONDON–(BUSINESS WIRE)–Forrester (Nasdaq: FORR) today announced the full conference agenda for Technology & Innovation EMEA, held in London and digitally 12–13 October 2023. As technology finds its way into every function of business, the role of the technology organisation and leader has changed. To stay competitive in today’s business environment, tech leaders need to anticipate the future needs of customers and align critical business capabilities — all underpinned by technology — to help their companies capture value and drive business growth.

At this year’s Technology & Innovation EMEA, chief information officers, chief technology officers, chief digital officers, and other technology leaders will learn best practices to help their organisations prioritise the right decisions, accelerate time to value, and deliver successful outcomes for customers and employees. They will also learn how to leverage emerging technologies such as generative AI to drive innovation and improve efficiency.

The event will include several guest keynote speakers, including noted author, Columbia Business School professor, and founder of the Mentora Institute, Hitendra Wadhwa, and Lloyds Banking Group head of digital delivery and strategy, Mitchell Nova, who will share how new technologies can enhance existing architecture platforms to spark transformation. Technology & Innovation EMEA will also honour EMEA recipients of Forrester’s Technology Awards, which recognise organisations that have successfully implemented technology strategies that are outcome-driven and customer-obsessed to accelerate business growth.

Noteworthy keynotes and sessions include:

Technology’s Role In Driving The Customer-Obsessed Growth Engine. This keynote discusses how tech executives must work with key stakeholders in their organisation to develop strategies that drive customer value and enable, create, and amplify growth.
Predictions 2024.Generative AI is exponentially gaining momentum within the future of work, editorial, customer experience, and code writing. In this keynote, learn about the next frontier of innovation threats, advantages, and opportunities in the year ahead.
The Metaverse Hype Is Over. The Real Work Continues. The metaverse does not exist yet, but precursors do, in consumer- and employee-facing scenarios. This session will discuss how companies are reaching consumers in virtual worlds and how they can make use of new environments for employee onboarding, training, and collaboration.
Fact Vs. Fiction: When Should You Invest In The Next Shiny Thing? Generative AI already has a key place in the enterprise technology portfolio. This session reveals the current state of the latest emerging technologies, what this means for enterprises, and the lessons that leaders can learn from early adopters of these technologies.
Digital Leaders Must Become Bolder To Plug Skill Gaps. Every organisation is facing skill gaps when tackling their broader digital transformation initiative. This session will discuss how most European business leaders have difficulty finding the digital talent they need and what they can do to combat this challenge.

“Regardless of the economic climate, technology and innovation is essential to driving business growth,” said Pascal Matzke, event host and VP, research director at Forrester. “Since CIOs and the IT organisation have the broadest span of control and visibility across business, processes, and data systems, they are in the best position to see the big picture and help prioritise initiatives that drive growth. At Technology & Innovation EMEA, tech leaders will learn how to develop resilient, adaptive, and creative strategies that inspire innovation, improve customer experiences, and supercharge business outcomes.”

In-person attendees will experience facilitated discussions, consulting workshops, and special programmes, including the Women’s Leadership Forum; the Executive Leadership Exchange, an exclusive programme targeted at C-level leaders; and several diversity and inclusion sessions. Digital attendees will have access to all conference sessions and sponsors via the event platform.

Resources:

Register to attend Forrester’s Technology & Innovation EMEA 2023 conference.
View the full agenda and speakers for Technology & Innovation EMEA 2023.
Learn about Technology & Innovation EMEA sponsorship opportunities.
Follow @Forrester and #ForrTech for updates.

About Forrester

Forrester (Nasdaq: FORR) is one of the most influential research and advisory firms in the world. We help leaders across technology, customer experience, digital, marketing, sales, and product functions use customer obsession to accelerate growth. Through Forrester’s proprietary research, consulting, and events, leaders from around the globe are empowered to be bold at work — to navigate change and put their customers at the centre of their leadership, strategy, and operations. Our unique insights are grounded in annual surveys of more than 700,000 consumers, business leaders, and technology leaders worldwide; rigorous and objective research methodologies, including Forrester Wave™ evaluations; 70 million real-time feedback votes; and the shared wisdom of our clients. To learn more, visit Forrester.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230918409305/en/

Naomi Thomas, 07917184752

[email protected]

KEYWORDS: United Kingdom Europe

INDUSTRY KEYWORDS: Consulting Other Professional Services Professional Services

MEDIA:

Logo

September 18, 2023 6:02 am

Forrester Announces Full Conference Agenda For B2B Summit EMEA 2023

Forrester Announces Full Conference Agenda For B2B Summit EMEA 2023

The event will showcase new research and best practices to help B2B marketing, sales, and product leaders achieve growth in a competitive environment

LONDON–(BUSINESS WIRE)–Forrester (Nasdaq: FORR) today announced the full conference agenda for its B2B Summit EMEA event, held in London and digitally from 9–11 October 2023. Given the current economic volatility, B2B leaders must move away from short-term goals to creating strategies that drive consistent, long-term customer and buyer value. The event will also share best practices for leveraging generative AI to transform sales and marketing.

At the event, B2B marketing, sales, and product leaders will explore new research, models, and insights to drive growth in a competitive market. They will learn how to improve cross-functional alignment — crucial to growth but not easy to achieve — in a changing landscape where buyer needs, economic uncertainty, and competition are unrelenting. The attendees will gain access to content to improve the efficiency and effectiveness of people, processes, and performance.

Noteworthy keynotes and sessions include:

Winning With Generative AI: Transforming Sales And Marketing. Join this keynote to learn how B2B marketing and sales leaders can use generative AI effectively and navigate its potential risks.

Introducing Forrester’s B2B Customer-Obsessed Growth Engine. To win customers and achieve growth, firms need a customer-obsessed growth engine that creates customer and buyer value and aligns marketing, sales, and product functions.

It’s About The Customer — How Marketing And Sales Integrate For Success. Buying practices and technology have changed faster than go-to-market practices, and buyers now have greater purchasing expectations. In this session, learn how to enable buyers to make purchases using digital buying signals.

The State Of B2B Marketing Measurement 2023. This session offers strategies for B2B marketers to align their measurement with their organisation’s growth strategies and stakeholder needs.

Get Ready For The Age Of Cookieless Marketing. Learn how to identify and assess the impact of privacy regulation on key marketing practices, as well as new technologies that can help marketers overcome specific challenges.

Additionally, Forrester will celebrate its B2B Return On Integration Honours and B2B Programmes Of The Year Awards winners to recognise organisations that have had outstanding achievements in marketing, sales, and product functions to drive revenue growth. In-person attendees in London can access all sponsors and onsite content, including facilitated discussions and special sessions such as the Executive Leadership Exchange and several diversity and inclusion sessions. Attendees of the B2B Summit digital experience will have access to all conference sessions, including keynotes, track sessions, case studies, and sponsors via the event platform.

“European leaders are in an odd economic and geopolitical environment with ambiguous, counterintuitive, and contradictory market signals,” said Forrester VP and Research Director Paul Ferron. “In addition, factors such as new privacy laws, generative AI’s rapid rise, and internal and external pressures to drive business growth quickly are putting tremendous pressure on B2B leaders. At B2B Summit EMEA, marketing and sales leaders will learn how to make smart decisions to enable greater success for their business.”

Resources:

Register to attend Forrester’s B2B Summit EMEA.
View the full agenda and speakers for B2B Summit EMEA.
Learn about B2B Summit EMEA sponsorship opportunities.
Access Forrester’s Planning Guide 2024: B2B Marketing Executives report to learn how marketers can accelerate their organisation’s growth engine in the year ahead.

About Forrester

Forrester is one of the most influential research and advisory firms in the world. We help leaders across technology, customer experience, digital, marketing, sales, and product functions use customer obsession to accelerate growth. Through Forrester’s proprietary research, consulting, and events, leaders from around the globe are empowered to be bold at work — to navigate change and put their customers at thecentre of their leadership, strategy, and operations. Our unique insights are grounded in annual surveys of more than 700,000 consumers, business leaders, and technology leaders worldwide; rigorous and objective research methodologies, including Forrester Wave™ evaluations; 70 million real-time feedback votes; and the shared wisdom of our clients.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230918288016/en/

Naomi Thomas

[email protected]

KEYWORDS: United Kingdom Europe

INDUSTRY KEYWORDS: Consulting Data Management Technology Professional Services Communications Other Technology Data Analytics Software Artificial Intelligence Hardware Content Marketing

MEDIA:

Logo

Posted on September 18, 2023 5:03 am
QuantaSing Expands Global Presence with Acquisition of Kelly’s Education

BEIJING, Sept. 18, 2023 (GLOBE NEWSWIRE) — QuantaSing Group Limited (NASDAQ: QSG) (“QuantaSing” or the “Company”), a leading online learning service provider in China, today announced its acquisition of Kelly’s Education, an online language education platform headquartered in Hong Kong. This transaction marks QuantaSing’s entry into the global online education market and the language learning sector. Following completion of the transaction, Kelly’s Education will become a wholly-owned subsidiary of the Company.

QuantaSing, known for its innovative online platforms like QiNiu for financial literacy, JiangZhen for lifelong learning, and QianChi for senior citizens’ interests, serves an extensive range of learning needs, empowering individuals to consistently enhance their self-value. Kelly’s Education provides personalized online language education for children aged 3-15, primarily in Hong Kong. The acquisition allows QuantaSing to tap into the global online learning and new language education sectors.

On its path to entering the global market, QuantaSing is excited to introduce Hong Kong Online Education (“HKOE”), a brand initially developed by Kelly’s Education, which offers high-quality online English education for children, with a focus on delivering value. HKOE adheres firmly to the belief that top-tier education should be within reach for a broader audience of children, not just a privileged few. By implementing a reasonable pricing strategy, HKOE is determined to make premium English education more affordable, presenting a range of course options that accommodate various needs and budgets.

Mr. Peng Li, Chairman and Chief Executive Officer of QuantaSing, said, “We are excited to integrate Kelly’s Education and the new brand HKOE into our ecosystem. We congratulate Ken and his team for developing such a strong offering and look forward to our partnership. Their strong business model and seasoned team lays a solid foundation for our global market entry. We plan to broaden our course offerings, including Chinese language learning, and diversify our revenue streams by appealing to a wider age group. We remain committed to fulfilling the ongoing demand from individuals seeking to improve their quality of life and overall well-being through our diverse course offerings.”

Mr. Ken Chau, newly appointed Senior Vice President of International Business at QuantaSing and founder of Kelly’s Education, has the mandate to expand the business globally while maintaining the high standard of courses through meaningful partnerships. Mr. Chau commented, “Joining forces with QuantaSing presents an exhilarating opportunity to leverage its strengths and extend our business reach globally. Our vision for the future encompasses not only broadening our reach but also continually adapting our offerings to meet the dynamic needs of learners worldwide.”

About QuantaSing Group Limited

QuantaSing is a leading online service provider in China dedicated to improving people’s quality of life and well-being by providing lifelong personal learning and development opportunities. The Company is the largest service provider in China’s online adult learning market and China’s adult personal interest learning market in terms of revenue, according to a report by Frost & Sullivan based on data from 2022. By leveraging its proprietary tools and technology, QuantaSing offers easy-to-understand, affordable, and accessible online courses to adult learners under a variety of brands, including QiNiu, JiangZhen, and QianChi, empowering users to pursue personal development. Leveraging its extensive experience in individual online learning services, the Company has also expanded its services to corporate clients including, among others, marketing services and enterprise talent management services.

For more information, please visit: https://ir.quantasing.com.

Contact

Leah Guo, Investor Relations
QuantaSing Group Limited
Email: [email protected]
Tel: +86 (10) 6493-7857

Robin Yang, Partner
ICR, LLC
Email: [email protected]
Tel: +1 (212) 537-0429

Public Relations
Brad Burgess, Senior Vice President
ICR, LLC
Email: [email protected]

Posted on September 18, 2023 5:03 am
Fortuna celebrates the inauguration of the Séguéla Mine in Côte d’Ivoire

VANCOUVER, British Columbia, Sept. 18, 2023 (GLOBE NEWSWIRE) — Fortuna Silver Mines Inc. (NYSE: FSM) (TSX: FVI) is pleased to announce that the inauguration ceremony of its Séguéla Mine in Côte d’Ivoire took place on Friday, September 15, 2023. The ceremony was attended by national, provincial, and local government authorities, representatives of the Canadian embassy, community representatives, local media, contractors, company personnel, and over 1,000 guests from the neighboring communities.

Jorge A. Ganoza, President and CEO of Fortuna, commented, “Séguéla is Fortuna’s fifth mine, and will be a flagship asset within our growing global portfolio. We are tremendously proud to celebrate its inauguration with our friends and partners in Côte d’Ivoire.” Mr. Ganoza continued, “This exciting milestone reflects our strategic commitment to West Africa, and we look forward to the value and benefits the Séguéla Mine will bring to all of our stakeholders for many years to come.”

From left: Fofana Bouaké, Minister of Hydraulics, Sanitation and Hygiene (Côte d’Ivoire); Jorge A. Ganoza, President and CEO of Fortuna; Mamadou Sangafowa Coulibaly, Minister of Mines, Petroleum and Energy (Côte d’Ivoire); Karim Diarrassouba, Prefect of the Séguéla Region (Côte d’Ivoire) Jorge A. Ganoza, President and CEO of Fortuna (background), and Mamadou Sangafowa Coulibaly, Minister of Mines, Petroleum and Energy (foreground), greet members of the community who attended the inauguration of the Séguéla Mine


Séguéla poured first gold on May 24, 2023 (refer to Fortuna news release dated May 25, 2023) and the processing plant has now produced a total of 21,716 ounces of gold in doré as of the end of August (refer to Fortuna news release dated September 7, 2023). The Company reiterates Séguéla´s 2023 annual production guidance of 60,000 to 75,000 ounces of gold (refer to Fortuna news release dated January 17, 2023).

Qualified Person

Eric Chapman, Senior Vice President of Technical Services of Fortuna, is a Professional Geoscientist registered with Engineers and Geoscientists British Columbia (Registration Number 36328) and a Qualified Person as defined by National Instrument 43-101- Standards of Disclosure for Mineral Projects. Mr. Chapman has reviewed and approved the scientific and technical information contained in this news release and has verified the underlying data.

About Fortuna Silver Mines Inc.

Fortuna Silver Mines Inc. is a Canadian precious metals mining company with five operating mines in Argentina, Burkina Faso, Côte d’Ivoire, Mexico, and Peru. Sustainability is integral to all our operations and relationships. We produce gold and silver and generate shared value over the long-term for our stakeholders through efficient production, environmental protection, and social responsibility. For more information, please visit our website.

ON BEHALF OF THE BOARD

Jorge A. Ganoza

President, CEO, and Director
Fortuna Silver Mines Inc.

Investor Relations:

Carlos Baca | [email protected] | www.fortunasilver.com | X | LinkedIn | YouTube

Forward looking Statements

This news release contains forward-looking statements which constitute “forward-looking information” within the meaning of applicable Canadian securities legislation and “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 (collectively, “Forward-looking Statements”). All statements included herein, other than statements of historical fact, are Forward-looking Statements and are subject to a variety of known and unknown risks and uncertainties which could cause actual events or results to differ materially from those reflected in the Forward-looking Statements. The Forward-looking Statements in this news release include, without limitation, statements about the Company’s plans for its mines and mineral properties; statements regarding the Company’s expectations for the length of operations at
Séguéla; estimated Séguéla production forecasts for 2023; the values and benefits of the Séguéla Mine to the Company’s stakeholders; and the Company’s business strategy, plans and outlook.
Often, but not always, these Forward-looking Statements can be identified by the use of words such as “estimated”, “potential”, “open”, “future”, “assumed”, “projected”, “used”, “detailed”, “has been”, “gain”, “planned”, “reflecting”, “will”, “anticipated”, “estimated” “containing”, “remaining”, “to be”, or statements that events, “could” or “should” occur or be achieved and similar expressions, including negative variations.

Forward-looking Statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any results, performance or achievements expressed or implied by the Forward-looking Statements. Such uncertainties and factors include, among others,
operational risks associated with mining and mineral processing; uncertainty relating to Mineral Resource and Mineral Reserve estimates; uncertainty relating to capital and operating costs, production schedules and economic returns; uncertainties related to new mining operations and development projects, including the possibility that actual capital and operating costs and economic returns will differ significantly from those estimated for such projects prior to production; risks relating to the Company’s ability to replace its Mineral Reserves; risks associated with mineral exploration and project development; uncertainty relating to the repatriation of funds as a result of currency controls; environmental matters including obtaining or renewing environmental permits and potential liability claims; uncertainty relating to nature and climate conditions; risks associated with political instability and changes to the regulations governing the Company’s business operations; changes in national and local government legislation, taxation, controls, regulations and political or economic developments in countries in which the Company does or may carry on business; risks associated with war, hostilities or other conflicts, such as the Ukrainian – Russian conflict, and the impact it may have on global economic activity; risks relating to the termination of the Company’s mining concessions in certain circumstances; developing and maintaining relationships with local communities and stakeholders; risks associated with losing control of public perception as a result of social media and other web-based applications; potential opposition to the Company’s exploration, development and operational activities; risks related to the Company’s ability to obtain adequate financing for planned exploration and development activities; property title matters; risks relating to the integration of businesses and assets acquired by the Company; impairments; risks associated with climate change legislation; reliance on key personnel; adequacy of insurance coverage; operational safety and security risks; legal proceedings and potential legal proceedings; the ability of the Company to successfully contest and revoke the resolution issued by SEMARNAT which annuls the extension of the environmental impact authorization for the San Jose Mine;
uncertainties relating to general economic conditions; risks relating to a global pandemic, which could impact the Company’s business, operations, financial condition and share price; competition; fluctuations in metal prices; risks associated with entering into commodity forward and option contracts for base metals production; fluctuations in currency exchange rates and interest rates; tax audits and reassessments; risks related to hedging; uncertainty relating to concentrate treatment charges and transportation costs; sufficiency of monies allotted by the Company for land reclamation; risks associated with dependence upon information technology systems, which are subject to disruption, damage, failure and risks with implementation and integration;
labour relations issues; as well as those factors discussed under “Risk Factors” in the Company’s Annual Information Form for the financial year ended December 31, 2022. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in Forward-looking Statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended.

Forward-looking Statements contained herein are based on the assumptions, beliefs, expectations and opinions of management, including but not limited to the accuracy of the Company’s current Mineral Resource and Mineral Reserve estimates; that the Company’s activities will be conducted in accordance with the Company’s public statements and stated goals; that there will be no material adverse change affecting the Company, its properties or its production estimates (which assume accuracy of projected ore grade, mining rates, recovery timing, and recovery rate estimates and may be impacted by unscheduled maintenance, labour and contractor availability and other operating or technical difficulties); the duration and effect of global and local inflation; geo-political uncertainties on the Company’s production, workforce, business, operations and financial condition; the expected trends in mineral prices, inflation and currency exchange rates; that the Company will be successful in challenging the annulment of the extension to the San Jose Mine environmental impact authorization; that all required approvals and permits will be obtained for the Company’s business and operations on acceptable terms; that there will be no significant disruptions affecting the Company’s operations and such other assumptions as set out herein. Forward-looking Statements are made as of the date hereof and the Company disclaims any obligation to update any Forward-looking Statements, whether as a result of new information, future events or results or otherwise, except as required by law. There can be no assurance that these Forward-looking Statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, investors should not place undue reliance on Forward-looking Statements.

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/0f2f75a8-66e5-4816-af42-f007bb8794ad

https://www.globenewswire.com/NewsRoom/AttachmentNg/8e52b568-fa96-4336-b642-f08d61e5bac8

Posted on September 18, 2023 4:47 am
Citi GPS: Cross-Border Payments to Transform Financial Industry, Ushering Best-in-Class Experiences for Clients

Citi GPS: Cross-Border Payments to Transform Financial Industry, Ushering Best-in-Class Experiences for Clients

LONDON–(BUSINESS WIRE)–
Citi has launched its latest Global Perspectives & Solutions (Citi GPS) report titled: ‘FUTURE OF CROSS-BORDER PAYMENTS — Who Will Be Moving $250 Trillion in the Next Five Years?’ Its findings indicate that the expected increase of cross-border payments presents a major opportunity for players in this space.

“Our vision to be the preeminent banking partner for institutions with cross-border needs grows ever more relevant every day. With international networks fully engaged and payment activity continuing to grow across borders, clients need solutions that meet their global needs,” says Jane Fraser, Chief Executive Officer, Citi.

“Our industry is on a journey to reach the next phase of evolution within cross-border payments. We’re partnering closely with financial institutions, FinTechs, corporates, and industry experts — all of whom have contributed their perspectives in this paper — to continue building best-in-class experiences for clients and using technologies such as artificial intelligence and digital assets to make it happen,” she adds. Concluding, “I’m excited to see the immense opportunity that the next five years will bring as we work together to transform cross-border payments.”

Cross-border payments is a large and growing business with expected 2022-27 growth rates in the high-single digits for innovative players who invest in this business. Cross-border payment volumes historically track merchandise trade growth, which should be in-line with nominal GDP growth. The Bank of England estimates that the value of cross-border payments is set to increase from almost $150 trillion in 2017 to over $250 trillion by 2027, equating to a rise of over $100 trillion in just 10 years. This presents a major opportunity for players to be part of the cross-border payments space.

Market share shifts will hurt some incumbents. According to a proprietary survey conducted by Citi, almost 90% of financial institution clients believe at least 5% of market share will be lost, predominantly to FinTechs, over the next 5-10 years, with 40% noting share of wallet had already been lost.

“Competition is increasingly multi-faceted within the industry. Payments are moving away from traditional instruction methods, which are tied to batch and files, and moving towards API connectivity”, says Shahmir Khaliq, Global Head of Services, Citi. “This is leading to a heightened opportunity for FinTechs and other participants that will be enabled through traditional financial infrastructures. Regulation is also increasingly fostering innovation via initiatives such as open banking and there has been a consequent increase in players that can deliver technology nimbly and leverage digital client experiences as a differentiating factor,” he adds.

Challenges exist in responding to how the industry is evolving, with legacy technologies in place and competing regulatory obligations to adhere to, both of which consume significant investment budgets. That said, our research revealed that financial institutions are focused on innovation and exploring this across traditional fiat currency and digital asset spaces. Fiat industry innovation focuses on a true 24×7 “always on” model, and initiatives exist to bring domestic offerings that are instant and 24×7 across borders. Alternative payment methods such as digital wallets provide another fiat solution to deliver faster, and cheaper payments.

“The world of cross-border payments has never been more attractive from a business opportunity perspective,” says Amit Agarwal, Global Co-Head Payments & Receivables, Citi Treasury and Trade Solutions. ”The growth of e-commerce and new business models such as marketplaces, d2c or shared economies have eliminated borders for companies and consumers alike, with cross-border payments growing alongside them driving advancements across speed, cost efficiency and transparency,” he adds. “At Citi’s Treasury and Trade Solutions, we have made it our key strategic objective to enable our financial institution clients who work with us to win share of their clients’ payments wallets through differentiated client experience,” says Debopama Sen, Global Co-Head Payments & Receivables, Citi Treasury and Trade Solutions. “This entails constant focus on delivering best in class scalable solutions focusing on addressing our clients’ and ultimately their clients’ clients pain points and opportunities.”

“The digital asset space, albeit promising, is still in its early days,” says Ronit Ghose, Head of Future of Finance, Citi Global Insights. “However cross-border payments providers must stay vigilant and ensure readiness to embrace this space if and when it is ready to scale, with CBDCs, stablecoins, and tokenized deposits in focus,” he adds. Key emerging technologies also have the ability to disrupt cross-border payments. Artificial intelligence could provide revenue streams through behavior prediction to cross-sell or to mitigate risk through fraud detection capabilities. The Metaverse could provide a new channel of payment experiences. Embedded finance and open banking can leverage application programming interfaces (APIs) to provide payment experiences in new places and across banking providers.

There is a greater emphasis on client experience, and the key ingredients to delivering a best-in-class cross-border payments experience include shifting to a client-centric culture and having an end-to end mindset, aiming for consolidation and simplification to improve the overall payments experience for clients, harnessing the power of data, and leveraging it to simplify the client experience. According to our proprietary survey, over 50% of financial institutions see the need to revamp front ends to improve client experience to compete against disruption.

This report builds on qualitative contributions from key market infrastructure experts from within and outside of Citi, FinTechs, and a diversified set of banks spanning across four continents. It also outlines the key findings from a survey of more than 100 of Citi’s financial institution clients. Their priorities were resoundingly clear: Speed, cost-efficiency and transparency are critical to delivering best-in-class client experiences.

The digital copy of the report is availableclick here .

About Citi’s Treasury and Trade Solutions

Citi Treasury and Trade Solutions (TTS) enables our clients’ success by providing an integrated suite of innovative and tailored cash management and trade finance services to multinational corporations, financial institutions and public sector organizations across the globe. Based on the foundation of the industry’s largest proprietary network with banking licenses in over 90 countries and globally integrated technology platforms, TTS continues to lead the way in offering one of the industry’s most comprehensive range of digitally enabled treasury, trade and liquidity management solutions.

About Citi Global Perspectives & Solutions (Citi GPS)

As our premier thought-leadership product, Citi Global Perspectives & Solutions (Citi GPS) is designed to help readers navigate the most demanding challenges and greatest opportunities of the 21st century. We access the best elements of our global conversation with senior Citi senior professionals, academics, and corporate leaders to anticipate themes and trends in today’s fast-changing and interconnected world.

About Citi

Citi is a preeminent banking partner for institutions with cross-border needs, a global leader in wealth management and a valued personal bank in its home market of the United States. Citi does business in more than 160 countries and jurisdictions, providing corporations, governments, investors, institutions and individuals with a broad range of financial products and services.

Additional information may be found at www.citigroup.com | Twitter: @Citi | www.youtube.com/citi | http://blog.citigroup.com | www.facebook.com/citi | www.linkedin.com/company/citi

View source version on businesswire.com: https://www.businesswire.com/news/home/20230918198934/en/

Media Contacts:

TTS: Nina Das ([email protected]) / Richard Bicknell ([email protected])

GPS: Francesco Meucci ([email protected])

KEYWORDS: United Kingdom Europe

INDUSTRY KEYWORDS: Banking Asset Management Professional Services Finance

MEDIA:

Logo

Posted on September 18, 2023 4:03 am
Kite’s Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma

Kite’s Car T-cell Therapy Yescarta^® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma

– Yescarta Achieved a Complete Metabolic Response (CMR) of 71% at 3 Months Versus 12% Expected with Historical Standard of Care Controls–

– Results Published in Nature Medicine–

SANTA MONICA, Calif.–(BUSINESS WIRE)–
Kite, a Gilead Company (Nasdaq: GILD), today announced results from the Phase 2 ALYCANTE study, led and sponsored by the French collaborative group LYSA/LYSARC, for use of its chimeric antigen receptor (CAR) T-cell therapy Yescarta^® (axicabtagene ciloleucel) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after one prior line of therapy who were deemed ineligible for high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT). The full findings from the study were published in Nature Medicine.

The ALYCANTE study, a multicenter, open-label Phase 2 LYSA study, evaluated for the first time the efficacy and safety of Yescarta as a second-line therapy in 62 patients with R/R LBCL who were deemed ineligible for HDCT and ASCT. The study met its primary endpoint, with a complete metabolic response (CMR) of 71% (n=44, 95% confidence interval [CI], 58.1%–81.8%) at 3 months versus 12% expected with standard of care (based on historical controls). At 6 months, 59.7% of patients (n=37) remained in CMR. CMR is defined as negative findings on a PET study during or following antitumor therapy.

“Transplant ineligible patients with aggressive relapsed or refractory B-cell lymphomas face poor prognosis,” said Prof. Roch Houot, Head of Haematology Department, University Hospital of Rennes, France and coordinator of the ALYCANTE study. “ALYCANTE is the first study to assess axicabtagene ciloleucel as second-line therapy for transplant ineligible R/R LBCL and the results showed high response rates and durable remission in this hard-to-treat population.”

Best objective response (OR) and complete response (CR) rates were 91.9% (n=57) and 82.3% (n=51), respectively. After a median follow-up of 12 months, median progression-free survival (PFS) from infusion was 11.8 months, and 48.8% (95% CI, 34.0-62.0%) of patients evaluated were alive and progression-free at 12 months. Median overall survival (OS) was not reached. OS at 12 months was 78.3% (95% CI, 64.7-87.1%). Yescarta showed an acceptable safety profile in this population, who are considered unfit for HDCT/ASCT; 8.1% (n=5) and 14.5% (n=9) experienced Grade 3-4 cytokine-release syndrome (CRS) or Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS), respectively.

In clinical practice, about half of patients with R/R LBCL are considered ineligible for HDCT/ASCT due to factors including advanced age, frailty, and coexisting medical conditions. The ALYCANTE study included patients deemed ineligible for HDCT/ASCT because of age ≥65 years (88.7%), high hematopoietic cell transplantation-specific comorbidity index score ≥3 (32.3%), and/or prior ASCT (3.2%).

“For patients who are deemed ineligible for stem cell transplant, the ALYCANTE data demonstrate that Yescarta can provide another option for a potential curative therapy,” said Frank Neumann, MD, PhD, SVP, Kite’s Global Head of Clinical Development. “The data generation for Yescarta continues to reaffirm its potential to bring hope to patients suffering from a variety of sub-types of large B-cell lymphoma and follicular lymphoma.”

About ALYCANTE study

ALYCANTE is a phase 2 study evaluating the efficacy and safety of axicabtagene ciloleucel in patients with R/R LBCL after one prior line of therapy who were deemed ineligible for high-dose chemotherapy and autologous stem cell transplantation, sponsored by the LYSA/LYSARC collaborative group (NCT04531046). The primary endpoint was the complete metabolic response (CMR) at 3 months from axicabtagene ciloleucel infusion. The study was funded by Kite, a Gilead Company, and carried out with axicabtagene ciloleucel CAR T-cell therapy manufactured by Kite.

About the LYSA/LYSARC Collaborative Group

LYSA, The Lymphoma Study Association, is a non-profit, internationally leading, academic cooperative group gathering multidisciplinary expertise in lymphoma. Its operational structure LYSARC, The Lymphoma Academic Research Organization, has all the integrated functions and platforms dedicated to pathology, biology and imaging to conduct multiple phase 1 to 4 clinical studies and registries. The LYSA has more than 500 members, researchers and medical experts, with a network of about 90 clinical research centers in France, Belgium and Portugal. The LYSA’s missions are to promote clinical research, to improve prevention, care and treatment of patients and to disseminate knowledge about all types of lymphoma.

About Yescarta

Please see full Prescribing Information, including BOXED WARNING and Medication Guide.

YESCARTA is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of:

Adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy.

Adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

Limitations of Use: YESCARTA is not indicated for the treatment of patients with primary central nervous system lymphoma.

Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

U.S. IMPORTANT SAFETY INFORMATION

BOXED WARNING: CYTOKINE RELEASE SYNDROME AND NEUROLOGIC TOXICITIES

Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving YESCARTA. Do not administer YESCARTA to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids.

Neurologic toxicities, including fatal or life-threatening reactions, occurred in patients receiving YESCARTA, including concurrently with CRS or after CRS resolution. Monitor for neurologic toxicities after treatment with YESCARTA. Provide supportive care and/or corticosteroids as needed.

YESCARTA is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the YESCARTA and TECARTUS REMS Program.

CYTOKINE RELEASE SYNDROME (CRS)

CRS, including fatal or life-threatening reactions, occurred. CRS occurred in 90% (379/422) of patients with non- Hodgkin lymphoma (NHL), including ≥ Grade 3 in 9%. CRS occurred in 93% (256/276) of patients with large B- cell lymphoma (LBCL), including ≥ Grade 3 in 9%. Among patients with LBCL who died after receiving YESCARTA, 4 had ongoing CRS events at the time of death. For patients with LBCL in ZUMA-1, the median time to onset of CRS was 2 days following infusion (range: 1-12 days) and the median duration was 7 days (range: 2-58 days). For patients with LBCL in ZUMA-7, the median time to onset of CRS was 3 days following infusion (range: 1-10 days) and the median duration was 7 days (range: 2-43 days). CRS occurred in 84% (123/146) of patients with indolent non-Hodgkin lymphoma (iNHL) in ZUMA- 5, including ≥ Grade 3 in 8%. Among patients with iNHL who died after receiving YESCARTA, 1 patient had an ongoing CRS event at the time of death. The median time to onset of CRS was 4 days (range: 1-20 days) and median duration was 6 days (range: 1-27 days) for patients with iNHL.

Key manifestations of CRS (≥ 10%) in all patients combined included fever (85%), hypotension (40%), tachycardia (32%), chills (22%), hypoxia (20%), headache (15%), and fatigue (12%). Serious events that may be associated with CRS include cardiac arrhythmias (including atrial fibrillation and ventricular tachycardia), renal insufficiency, cardiac failure, respiratory failure, cardiac arrest, capillary leak syndrome, multi-organ failure, and hemophagocytic lymphohistiocytosis/macrophage activation syndrome.

The impact of tocilizumab and/or corticosteroids on the incidence and severity of CRS was assessed in 2 subsequent cohorts of LBCL patients in ZUMA-1. Among patients who received tocilizumab and/or corticosteroids for ongoing Grade 1 events, CRS occurred in 93% (38/41), including 2% (1/41) with Grade 3 CRS; no patients experienced a Grade 4 or 5 event. The median time to onset of CRS was 2 days (range: 1-8 days) and the median duration of CRS was 7 days (range: 2-16 days). Prophylactic treatment with corticosteroids was administered to a cohort of 39 patients for 3 days beginning on the day of infusion of YESCARTA. Thirty-one of the 39 patients (79%) developed CRS and were managed with tocilizumab and/or therapeutic doses of corticosteroids with no patients developing ≥ Grade 3 CRS. The median time to onset of CRS was 5 days (range: 1-15 days) and the median duration of CRS was 4 days (range: 1-10 days). Although there is no known mechanistic explanation, consider the risk and benefits of prophylactic corticosteroids in the context of pre-existing comorbidities for the individual patient and the potential for the risk of Grade 4 and prolonged neurologic toxicities.

Ensure that 2 doses of tocilizumab are available prior to YESCARTA infusion. Monitor patients for signs and symptoms of CRS at least daily for 7 days at the certified healthcare facility, and for 4 weeks thereafter. Counsel patients to seek immediate medical attention should signs or symptoms of CRS occur at any time. At the first sign of CRS, institute treatment with supportive care, tocilizumab, or tocilizumab and corticosteroids as indicated.

NEUROLOGIC TOXICITIES

Neurologic toxicities (including immune effector cell-associated neurotoxicity syndrome) that were fatal or life- threatening occurred. Neurologic toxicities occurred in 78% (330/422) of all patients with NHL receiving YESCARTA, including ≥ Grade 3 in 25%. Neurologic toxicities occurred in 87% (94/108) of patients with LBCL in ZUMA-1, including ≥ Grade 3 in 31% and in 74% (124/168) of patients in ZUMA-7 including ≥ Grade 3 in 25%. The median time to onset was 4 days (range: 1-43 days) and the median duration was 17 days for patients with LBCL in ZUMA-1. The median time to onset for neurologic toxicity was 5 days (range:1- 133 days) and median duration was 15 days in patients with LBCL in ZUMA-7. Neurologic toxicities occurred in 77% (112/146) of patients with iNHL, including ≥ Grade 3 in 21%. The median time to onset was 6 days (range: 1-79 days) and the median duration was 16 days. Ninety-eight percent of all neurologic toxicities in patients with LBCL and 99% of all neurologic toxicities in patients with iNHL occurred within the first 8 weeks of YESCARTA infusion. Neurologic toxicities occurred within the first 7 days of infusion for 87% of affected patients with LBCL and 74% of affected patients with iNHL.

The most common neurologic toxicities (≥ 10%) in all patients combined included encephalopathy (50%), headache (43%), tremor (29%), dizziness (21%), aphasia (17%), delirium (15%), and insomnia (10%). Prolonged encephalopathy lasting up to 173 days was noted. Serious events, including aphasia, leukoencephalopathy, dysarthria, lethargy, and seizures occurred. Fatal and serious cases of cerebral edema and encephalopathy, including late-onset encephalopathy, have occurred.

The impact of tocilizumab and/or corticosteroids on the incidence and severity of neurologic toxicities was assessed in 2 subsequent cohorts of LBCL patients in ZUMA-1. Among patients who received corticosteroids at the onset of Grade 1 toxicities, neurologic toxicities occurred in 78% (32/41) and 20% (8/41) had Grade 3 neurologic toxicities; no patients experienced a Grade 4 or 5 event. The median time to onset of neurologic toxicities was 6 days (range: 1-93 days) with a median duration of 8 days (range: 1-144 days). Prophylactic treatment with corticosteroids was administered to a cohort of 39 patients for 3 days beginning on the day of infusion of YESCARTA. Of those patients, 85% (33/39) developed neurologic toxicities, 8% (3/39) developed Grade 3, and 5% (2/39) developed Grade 4 neurologic toxicities. The median time to onset of neurologic toxicities was 6 days (range: 1-274 days) with a median duration of 12 days (range: 1-107 days). Prophylactic corticosteroids for management of CRS and neurologic toxicities may result in higher grade of neurologic toxicities or prolongation of neurologic toxicities, delay the onset and decrease the duration of CRS.

Monitor patients for signs and symptoms of neurologic toxicities at least daily for 7 days at the certified healthcare facility, and for 4 weeks thereafter, and treat promptly.

REMS

Because of the risk of CRS and neurologic toxicities, YESCARTA is available only through a restricted program called the YESCARTA and TECARTUS REMS Program which requires that: Healthcare facilities that dispense and administer YESCARTA must be enrolled and comply with the REMS requirements and must have on-site, immediate access to a minimum of 2 doses of tocilizumab for each patient for infusion within 2 hours after YESCARTA infusion, if needed for treatment of CRS. Certified healthcare facilities must ensure that healthcare providers who prescribe, dispense, or administer YESCARTA are trained about the management of CRS and neurologic toxicities. Further information is available at www.YescartaTecartusREMS.com or 1-844-454-KITE (5483).

HYPERSENSITIVITY REACTIONS

Allergic reactions, including serious hypersensitivity reactions or anaphylaxis, may occur with the infusion of YESCARTA.

SERIOUS INFECTIONS

Severe or life-threatening infections occurred. Infections (all grades) occurred in 45% of patients with NHL. Grade 3 or higher infections occurred in 17% of patients, including ≥ Grade 3 or higher infections with an unspecified pathogen in 12%, bacterial infections in 5%, viral infections in 3%, and fungal infections in 1%. YESCARTA should not be administered to patients with clinically significant active systemic infections. Monitor patients for signs and symptoms of infection before and after infusion and treat appropriately. Administer prophylactic antimicrobials according to local guidelines.

Febrile neutropenia was observed in 36% of all patients with NHL and may be concurrent with CRS. In the event of febrile neutropenia, evaluate for infection and manage with broad-spectrum antibiotics, fluids, and other supportive care as medically indicated.

In immunosuppressed patients, including those who have received YESCARTA, life-threatening and fatal opportunistic infections including disseminated fungal infections (e.g., candida sepsis and aspergillus infections) and viral reactivation (e.g., human herpes virus-6 [HHV-6] encephalitis and JC virus progressive multifocal leukoencephalopathy [PML]) have been reported. The possibility of HHV-6 encephalitis and PML should be considered in immunosuppressed patients with neurologic events and appropriate diagnostic evaluations should be performed. Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients treated with drugs directed against B cells, including YESCARTA. Perform screening for HBV, HCV, and HIV in accordance with clinical guidelines before collection of cells for manufacturing.

PROLONGED CYTOPENIAS

Patients may exhibit cytopenias for several weeks following lymphodepleting chemotherapy and YESCARTA infusion. ≥ Grade 3 cytopenias not resolved by Day 30 following YESCARTA infusion occurred in 39% of all patients with NHL and included neutropenia (33%), thrombocytopenia (13%), and anemia (8%). Monitor blood counts after infusion.

HYPOGAMMAGLOBULINEMIA

B-cell aplasia and hypogammaglobulinemia can occur. Hypogammaglobulinemia was reported as an adverse reaction in 14% of all patients with NHL. Monitor immunoglobulin levels after treatment and manage using infection precautions, antibiotic prophylaxis, and immunoglobulin replacement. The safety of immunization with live viral vaccines during or following YESCARTA treatment has not been studied. Vaccination with live virus vaccines is not recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy, during YESCARTA treatment, and until immune recovery following treatment.

SECONDARY MALIGNANCIES

Secondary malignancies may develop. Monitor life-long for secondary malignancies. In the event that one occurs, contact Kite at 1-844-454-KITE (5483) to obtain instructions on patient samples to collect for testing.

EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

Due to the potential for neurologic events, including altered mental status or seizures, patients are at risk for altered or decreased consciousness or coordination in the 8 weeks following YESCARTA infusion. Advise patients to refrain from driving and engaging in hazardous occupations or activities, such as operating heavy or potentially dangerous machinery, during this initial period.

ADVERSE REACTIONS

The most common non-laboratory adverse reactions (incidence ≥ 20%) in patients with LBCL in ZUMA-7 included fever, CRS, fatigue, hypotension, encephalopathy, tachycardia, diarrhea, headache, musculoskeletal pain, nausea, febrile neutropenia, chills, cough, infection with unspecified pathogen, dizziness, tremor, decreased appetite, edema, hypoxia, abdominal pain, aphasia, constipation, and vomiting.

The most common adverse reactions (incidence ≥ 20%) in patients with LBCL in ZUMA-1 included CRS, fever, hypotension, encephalopathy, tachycardia, fatigue, headache, decreased appetite, chills, diarrhea, febrile neutropenia, infections with pathogen unspecified, nausea, hypoxia, tremor, cough, vomiting, dizziness, constipation, and cardiac arrhythmias.

The most common non-laboratory adverse reactions (incidence ≥ 20%) in patients with iNHL in ZUMA-5 included fever, CRS, hypotension, encephalopathy, fatigue, headache, infections with pathogen unspecified, tachycardia, febrile neutropenia, musculoskeletal pain, nausea, tremor, chills, diarrhea, constipation, decreased appetite, cough, vomiting, hypoxia, arrhythmia, and dizziness.

About Kite

Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on cell therapy to treat and potentially cure cancer. As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company. Kite has the largest in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial production and commercial product manufacturing.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead Sciences acquired Kite in 2017.

Forward-Looking Statements

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the ability of Gilead and Kite to initiate, progress or complete clinical trials within currently anticipated timelines or at all, and the possibility of unfavorable results from ongoing or additional clinical studies, including those involving Yescarta; the possibility that Gilead and Kite may make a strategic decision to discontinue development of Yescarta for indications currently under evaluation and, as a result, Yescarta may never be successfully commercialized for such indications; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and factors are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead and Kite, and Gilead and Kite assume no obligation and disclaim any intent to update any such forward-looking statements.

U.S. Prescribing Information for Yescarta including BOXED WARNING, is available at www.kitepharma.com and www.gilead.com.

Kite, the Kite logo, Yescarta, and GILEAD are trademarks of Gilead Sciences, Inc. or its related companies.

For more information on Kite, please visit the company’s website at www.kitepharma.com. Follow Kite on social media on X (@KitePharma) and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230918662167/en/

Jacquie Ross, Investors

[email protected]

Anna Padula, Media

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Biotechnology Hospitals Health Pharmaceutical Clinical Trials

MEDIA:

Logo

Posted on September 18, 2023 3:08 am
B2Gold to Consolidate Gramalote Project by Acquiring AngloGold Ashanti’s 50% Stake

VANCOUVER, British Columbia, Sept. 18, 2023 (GLOBE NEWSWIRE) — B2Gold Corp. (TSX: BTO, NYSE AMERICAN: BTG, NSX: B2G) (“B2Gold” or the “Company”) is pleased to announce that is has entered into a purchase agreement with AngloGold Ashanti Limited (“AngloGold”) to acquire AngloGold’s 50% stake in the Gramalote project (the “Transaction”), located in the Department of Antioquia, Colombia (the “Gramalote Project”). Upon completion of the Transaction, B2Gold will own 100% of the Gramalote Project.

Transaction Highlights

Consolidates the Gramalote Project under one owner, providing additional optionality to analyze lower capital intensity, higher-return development opportunities for the Project: Historically, the Gramalote Project has been advanced under a joint venture between B2Gold and AngloGold, which has led to analyzing the project on a larger scale basis to provide meaningful production growth to both companies. Under a single owner, different development opportunities will be assessed with the goal of delineating a project that maximizes the return for B2Gold as sole owner of the Gramalote Project.

Accretive to B2Gold shareholders on a total gold resource per share basis: With the Transaction, B2Gold will add 2.11 million gold ounces of Indicated Mineral Resources and 0.74 million gold ounces of Inferred Mineral Resources to the Company’s consolidated Mineral Resource base.

B2Gold’s in-house projects team to commence work on various smaller scale project development plans, with the goal of identifying a higher-return project than the previously contemplated joint venture development plan: Based on the results of the 2022 Gramalote feasibility study, the contemplated larger scale project did not meet the combined investment return thresholds for development by both B2Gold and AngloGold. B2Gold plans to commence a detailed review of the Gramalote Project, including the facility size and location, power supply, mining and processing options, tailings design, resettlement, potential construction sequencing and camp design to identify potential cost savings to develop a smaller scale project. The results of the review will allow the Company to determine the optimal parameters and assumptions for a formal study, to commence in the fourth quarter of 2023, with the goal of completing an initial assessment by the end of the second quarter of 2024.

Transaction Terms and Conditions

Under the terms of the Transaction, the purchase price will be paid in cash and consist of the following payments to AngloGold based on, and contingent upon, certain milestones:

US$20 million upon closing of the Transaction;

US$10 million upon B2Gold announcing a construction decision at the Gramalote Project;

US$10 million upon commercial production at the Gramalote Project, contingent on commercial production beginning within five years of closing of the Transaction;

If commercial production does not commence within five years of closing of the Transaction, no payment will be made;

US$10 million on the first anniversary of commercial production at the Gramalote Project; and

US$10 million on the second anniversary of commercial production at the Gramalote Project.

Upon completon of the Transaction, the structure of the Transaction immediately adds to B2Gold’s consolidated Mineral Resource base and significantly increases the Company’s exposure to the upside from the potential development of the Gramalote Project, while still providing ongoing exposure to AngloGold through the contingent payments, which make up the majority of the purchase price. The Transaction is in line with B2Gold’s strategy of executing on accretive opportunities, increasing Mineral Reserves and Resources and continuing to advance development projects.

The B2Gold Board of Directors has unanimously approved the Transaction. The Transaction is subject to South African Reserve Bank approval and the satisfaction of customary closing conditions. Subject to the satisfaction of these conditions, B2Gold expects that the Transaction will be completed in the fourth quarter of 2023.

About B2Gold

B2Gold is a low-cost international senior gold producer headquartered in Vancouver, Canada. Founded in 2007, today, B2Gold has operating gold mines in Mali, Namibia and the Philippines, a mine under construction in northern Canada and numerous development and exploration projects in various countries including Mali, Colombia and Finland. B2Gold forecasts total consolidated gold production of between 1,000,000 and 1,080,000 ounces in 2023.

Qualified Persons

Brian Scott, P. Geo., Vice President, Geology & Technical Services, a qualified person under NI 43-101, has approved the scientific and technical information related to exploration and mineral resource matters contained in this news release.

ON BEHALF OF B2GOLD CORP.

“Clive T. Johnson”
President and Chief Executive Officer

For more information on B2Gold please visit the Company website at www.b2gold.com or contact:

Michael McDonald
VP, Investor Relations & Corporate Development
+1 604-681-8371
[email protected]

Cherry DeGeer
Director, Corporate Communications
+1 604-681-8371
[email protected]

The Toronto Stock Exchange and NYSE American LLC neither approve nor disapprove the information contained in this news release.

Production guidance presented in this news release reflect total production at the mines B2Gold operates on a 100% project basis. Please see our Annual Information Form dated March 16, 2023 for a discussion of our ownership interest in the mines B2Gold operates.

This news release includes certain “forward-looking information” and “forward-looking statements” (collectively “forward-looking statement”) within the meaning of applicable Canadian and United States securities legislation, including: projections; outlook; guidance; forecasts; estimates; statements regarding future or estimated financial and operational performance, gold production and sales, revenues and cash flows, and capital costs (sustaining and non-sustaining) and operating costs, and including, without limitation: total consolidated gold production of between 1,000,000 and 1,080,000 ounces in 2023; the Transaction being completed in the fourth quarter of 2023; and the receipt of regulatory approvals and satisfaction of conditions of the Transaction. All statements in this news release that address events or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, although not always, identified by words such as “expect”, “plan”, “anticipate”, “project”, “target”, “potential”, “schedule”, “forecast”, “budget”, “estimate”, “intend” or “believe” and similar expressions or their negative connotations, or that events or conditions “will”, “would”, “may”, “could”, “should” or “might” occur. All such forward-looking statements are based on the opinions and estimates of management as of the date such statements are made.

Forward-looking statements necessarily involve assumptions, risks and uncertainties, certain of which are beyond B2Gold’s control, including risks associated with or related to: the volatility of metal prices and B2Gold’s common shares; changes in tax laws; the dangers inherent in exploration, development and mining activities; the uncertainty of reserve and resource estimates; not achieving production, cost or other estimates; actual production, development plans and costs differing materially from the estimates in B2Gold’s feasibility and other studies; the ability to obtain and maintain any necessary permits, consents or authorizations required for mining activities; environmental regulations or hazards and compliance with complex regulations associated with mining activities; climate change and climate change regulations; the ability to replace mineral reserves and identify acquisition opportunities; the unknown liabilities of companies acquired by B2Gold; the ability to successfully integrate new acquisitions; fluctuations in exchange rates; the availability of financing; financing and debt activities, including potential restrictions imposed on B2Gold’s operations as a result thereof and the ability to generate sufficient cash flows; operations in foreign and developing countries and the compliance with foreign laws, including those associated with operations in Mali, Namibia, the Philippines and Colombia and including risks related to changes in foreign laws and changing policies related to mining and local ownership requirements or resource nationalization generally, including in response to the COVID-19 outbreak; remote operations and the availability of adequate infrastructure; fluctuations in price and availability of energy and other inputs necessary for mining operations; shortages or cost increases in necessary equipment, supplies and labour; regulatory, political and country risks, including local instability or acts of terrorism and the effects thereof; the reliance upon contractors, third parties and joint venture partners; the lack of sole decision-making authority related to Filminera Resources Corporation, which owns the Masbate Project; challenges to title or surface rights; the dependence on key personnel and the ability to attract and retain skilled personnel; the risk of an uninsurable or uninsured loss; adverse climate and weather conditions; litigation risk; competition with other mining companies; community support for B2Gold’s operations, including risks related to strikes and the halting of such operations from time to time; conflicts with small scale miners; failures of information systems or information security threats; the ability to maintain adequate internal controls over financial reporting as required by law, including Section 404 of the Sarbanes-Oxley Act; compliance with anti-corruption laws, and sanctions or other similar measures; social media and B2Gold’s reputation; risks affecting Calibre having an impact on the value of the Company’s investment in Calibre, and potential dilution of our equity interest in Calibre; as well as other factors identified and as described in more detail under the heading “Risk Factors” in B2Gold’s most recent Annual Information Form, B2Gold’s current Form 40-F Annual Report and B2Gold’s other filings with Canadian securities regulators and the U.S. Securities and Exchange Commission (the “SEC”), which may be viewed at www.sedar.com and www.sec.gov, respectively (the “Websites”). The list is not exhaustive of the factors that may affect B2Gold’s forward-looking statements

B2Gold’s forward-looking statements are based on the applicable assumptions and factors management considers reasonable as of the date hereof, based on the information available to management at such time. These assumptions and factors include, but are not limited to, assumptions and factors related to B2Gold’s ability to carry on current and future operations, including: the timing, extent, duration and economic viability of such operations, including any mineral resources or reserves identified thereby; the accuracy and reliability of estimates, projections, forecasts, studies and assessments; B2Gold’s ability to meet or achieve estimates, projections and forecasts; the availability and cost of inputs; the price and market for outputs, including gold; foreign exchange rates; taxation levels; the timely receipt of necessary approvals or permits; the ability to meet current and future obligations; the ability to obtain timely financing on reasonable terms when required; the current and future social, economic and political conditions; and other assumptions and factors generally associated with the mining industry.

B2Gold’s forward-looking statements are based on the opinions and estimates of management and reflect their current expectations regarding future events and operating performance and speak only as of the date hereof. B2Gold does not assume any obligation to update forward-looking statements if circumstances or management’s beliefs, expectations or opinions should change other than as required by applicable law. There can be no assurance that forward-looking statements will prove to be accurate, and actual results, performance or achievements could differ materially from those expressed in, or implied by, these forward-looking statements. Accordingly, no assurance can be given that any events anticipated by the forward-looking statements will transpire or occur, or if any of them do, what benefits or liabilities B2Gold will derive therefrom. For the reasons set forth above, undue reliance should not be placed on forward-looking statements.

Posts pagination

Previous page Page 1 … Page 13,717 Page 13,718 Page 13,719 … Page 39,982 Next page